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ABSTRACT 
 
Circulating ceramide levels are abnormally elevated in age-dependent pathologies such as cardiovascular 
diseases, obesity and Alzheimer’s disease. Nevertheless, the potential impact of age on plasma ceramide levels 
has not yet been systematically examined. In the present study, we quantified a focused panel of plasma 
ceramides and dihydroceramides in a cohort of 164 subjects (84 women) 19 to 80 years of age. After adjusting 
for potential confounders, multivariable linear regression analysis revealed a positive association between age 
and ceramide (d18:1/24:0) (β (SE) = 5.67 (2.38); p = .0198) and ceramide (d18:1/24:1) (β (SE) = 2.88 (.61); p < 
.0001) in women, and between age and ceramide (d18:1/24:1) in men (β (SE) = 1.86 (.77); p = .0179). In women 
of all ages, but not men, plasma ceramide (d18:1/24:1) was negatively correlated with plasma estradiol (r = -
0.294; p = .007). Finally, in vitro experiments in human cancer cells expressing estrogen receptors showed that 
incubation with estradiol (10 nM, 24 h) significantly decreased ceramide accumulation. Together, the results 
suggest that aging is associated with an increase in circulating ceramide levels, which in post-menopausal 
women is at least partially associated with lower estradiol levels. 
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INTRODUCTION 
 
The ceramides are key lipid constituents of mammalian 
cells. They regulate the structural properties of the lipid 
bilayer [1] along with its interaction with cellular 
proteins [2], and control many signalling processes, 
including cell survival [3], growth and proliferation [4], 
differentiation [5], senescence [6] and apoptosis [7, 8]. 
Dysfunctions in ceramide-mediated signalling may 
contribute to the initiation and progression of a variety 
of age-dependent diseases. Human studies have shown 
the existence of abnormal plasma levels of various 
ceramide species – including ceramide (d18:1/18:0), 
(d18:1/22:0), (d18:1/24:0) and (d18:1/24:1) – in several 
conditions such as obesity [9], type-2 diabetes [10], 
hypertension [11], atherosclerosis [12] and other 
cardiovascular diseases [13]. Furthermore, elevated 
serum levels of long-chain ceramides have been linked 
to the increased risk of memory deficits [14] and may 
be predictive of hippocampal volume loss and cognitive 
decline in patients affected by mild cognitive 
impairment [15]. Other studies have reported the 
existence of sex-dependent differences in circulating 
ceramides, albeit with apparently contrasting results 
[16-18]. For example, in a study of a large cohort of 
Mexican-Americans of median age 35.7 years, plasma 
ceramides were found to be higher in men than in 
women [17]. By contrast, in the Baltimore Longitudinal 
Study of Aging, whose participants were aged 55 or 
older, plasma ceramide concentrations were shown to 
be higher in women than in men [18]. These 
discrepancies may reflect across-study differences in 
design and participation.  
 
Aging in rats and mice is associated with sexually 
dimorphic changes in the sphingolipid composition of 
several brain structures, including the hippocampus 
[19]. Age-dependent sphingolipid alterations have also 
been documented in peripheral rodent tissues [20]. In 
the present study, we hypothesized that aging in humans 
might be similarly associated with changes in ceramide 
levels. To test this idea, we profiled six ceramides and 
dihydroceramide species in lipid extracts of plasma 
from 164 subjects (84 women) of age 19 to 80 years, 
using liquid chromatography/mass spectrometry (LC-
MS/MS).  
 
RESULTS 
 
Plasma ceramide levels in women are positively 
correlated with age 
 
An initial analysis of the data revealed the existence of a 
statistically detectable interaction between sex and 
ceramide levels, which prompted us to focus our 
attention on age-dependent changes occurring in either 
sex. The scatter plot reported in Fig 1A illustrates the 
total ceramide levels in plasma of individual women 
aged 20-78 years. Pearson’s analysis of the data 
revealed a statistically significant positive correlation 
 
 
Figure 1. Scatter plot of plasma ceramide concentrations in women aged 20 to 78 years. (A) Total ceramide levels in 84 
female subjects included in the study. Pearson’s correlation is considered statistically signiﬁcant at p < .05. (B) Average levels of 
individual ceramide species in pre-menopausal women (20-54 years, n = 44, open bars) and post-menopausal women (47-78 years, n 
= 40, closed bars). Results are expressed as mean ± SEM. *p < .05, **p < .01, ***p < .001; unpaired Student’s t-test. 
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between ceramide levels and age (r = 0.378; p = .0004). 
Because the largest accrual in plasma ceramides 
occurred between the age of 40 and 50 years, which is 
coincident with menopause, in a secondary analysis we 
grouped the data according to the subjects’ menopausal 
status. We found a statistically detectable difference 
between pre-menopausal women (20-54 years) and 
post-menopausal women (47-78 years) (Fig 1B). In 
particular, the levels of long-chain ceramide 
(d18:1/18:0) (p = .0035, unpaired Student’s t-test), very 
long-chain ceramides (d18:1/24:0) (p = .0012) and 
(d18:1/24:1) (p < .0001), and dihydroceramide 
(d18:0/24:1) (p = .0340) were higher in post-
menopausal relative to pre-menopausal women (Fig 
1B). No differences were found in the levels of 
ceramide (d18:1/16:0) (p = .3526) and dihydroceramide 
(d18:0/24:0) (p = .3633). In contrast with these findings 
in women, men showed no significant age-dependent 
increases in plasma ceramides (r = 0.143; p = .208) (Fig 
2A). Male subjects in the age groups 19-54 and 55-80 
years displayed comparable levels of circulating 
ceramide (d18:1/18:0) (p = .7112), (d18:1/24:0) (p = 
.7895), (d18:1/24:1) (p = .0847) and dihydroceramide 
(d18:0/24:1) (p = .9014). However, dihydroceramide 
(d18:0/24:0) was significantly lower in men >55 years, 
compared to younger men (p = .0003) (Fig 2B).  
 
In an additional analysis, we compared total ceramide 
levels in plasma of pre- and post-menopausal women 
with those measured in men of the same age group (Fig 
3). The results show that pre-menopausal women had 
significantly lower levels of circulating ceramides (p < 
.05, 2-way ANOVA followed by Bonferroni post-hoc 
test) relative to men of similar age (Fig 3A). The 
difference disappeared after menopause (p > .05) (Fig 
3A). 
 
Variables associated with plasma ceramides  
 
Next, we used multivariable linear regression models to 
test the association between age and ceramides and 
adjust for potential covariates for which data had been 
collected (Table 1). These factors included hypertension 
(32/164 subjects, 16 women), tobacco smoking (23/164 
subjects, 17 women), use of anti-hypercholesterol 
(12/164 subjects, 3 women) or contraceptive agents 
(6/164 subjects, 6 women), obesity (0/164 subjects) and 
diabetes (0/164 subjects). We did not take into account 
the number of cigarettes smoked as a variable of 
multivariable linear regression analysis. Plasma lipid 
levels were not collected for these samples. The 
adjusted linear regression analysis confirmed that 
ceramide (d18:1/24:0) (β (SE) = 5.67 (2.38); p = .0198) 
and ceramide (d18:1/24:1) (β (SE) = 2.88 (0.61); p < 
.0001) were positively associated with age in women 
and also, unexpectedly, revealed an opposite, albeit 
weaker, trend with ceramide (d18:1/16:0) (β (SE) = -.08 
(.04); p = .0285) (Table 2A). Interestingly, the analysis 
also pointed to a significant association, found only in 
women, between hypertension and ceramide 
(d18:1/16:0) (β (SE) = 4.78 (1.42); p = .0012) and 
(d18:1/18:0) (β (SE) = 2.48 (.97); p = .0126) (Table 
 
 
Figure 2. Scatter plot of plasma ceramide concentrations in men aged 19 to 80 years. (A) Total ceramide levels in 80 male 
subjects included in the study. Pearson’s correlation is considered statistically signiﬁcant at p < .05. (B) Average levels of individual 
ceramide species in men aged 19-54 years (n = 48, open bars) and 55-80 years (n = 32, closed bars). Results are expressed as mean ± 
SEM. *p < .05, **p < .01, ***p < .001; unpaired Student’s t-test.    
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2A). Of note, 15 out of 16 women affected by 
hypertension were in the post-menopausal group. In 
men (Table 2B), the analysis unmasked a statistically 
detectable association between age and ceramide 
(d18:1/24:1) (β (SE) = 1.86 (.77); p = .0179). Finally, 
we found no associations, in either sex, between 
ceramide levels and any other variable, including 
smoking, contraceptive use or anti-hypercholesterol 
agents, obesity and diabetes (Table 2A-B). 
Plasma ceramide levels are negatively correlated 
with estradiol in women, but not in men 
 
Next, we investigated a possible association between 
plasma levels of estradiol, which are known to fall 
significantly at menopause, and ceramides. Estradiol 
was measured with a competitive binding 
immunoassay. As expected, plasma estradiol was higher 
in pre-menopausal women (<55 years) compared to 
men in the same age group (p < .001, 2-way ANOVA 
followed by Bonferroni post-hoc test) (Fig 3B). After 
menopause, estradiol levels sharply decreased in both 
sexes (Fig 3B). Fig 4 illustrates the results of Pearson’s 
analyses of ceramide levels in female subjects of all 
ages. The results show a statistically significant 
negative correlation between estradiol and ceramide 
(d18:1/24:1) (r = -0.294; p = .007), a non-significant 
negative trend between estradiol and ceramide 
(d18:1/24:0) (r = -0.202; p = .066) and no correlations 
between estradiol and other ceramide species. By 
contrast, in men, no correlation was observed between 
estradiol and any ceramide species, including ceramide 
(d18:1/24:1) (r = -0.034; p = .763) (Fig 5), which was 
found to be correlated with aging (β (SE) = 1.86 (.77); p 
= .0179) (Table 2B).   
 
Estradiol suppresses ceramide accumulation in vitro 
 
Sphingolipid-derived mediators such as ceramide, 
sphingosine, and sphingosine-1-phosphate regulate 
steroidogenesis [21], but it is still unknown whether 
estrogen hormones influence sphingolipid metabolism. 
To gain insight into the causality of the negative 
correlation observed between estradiol and ceramide in 
women, we asked whether the sex hormone might 
regulate ceramide mobilization (i.e. formation and/or 
degradation) in human MCF7 breast cancer cells, a cell 
line that expresses the estrogen receptor α (ERα) and β 
(ERβ) [22]. MCF7 cells were treated with estradiol (10 
nM) for 24 h and ceramides quantified in lipid extracts 
by LC-MS/MS. Results indicate that the exposure to 
estradiol causes a substantial reduction in ceramide 
(d18:1/16:0) (p = .02, unpaired Student’s t-test), 
(d18:1/24:0) (p = .0002) and (d18:1/24:1) (p = .0006) 
(Table 3), thereby suggesting that estradiol causes a 
downregulation in the biosynthesis or/and an 
upregulation in the degradation of these substances. 
 
DISCUSSION 
 
In the present study, we investigated the age- and sex-
dependent trajectories of plasma ceramides in 80 men 
and 84 women aged 19-80 years. The results show that, 
in women, plasma levels of two ceramide species – 
(d18:1/24:0) and (d18:1/24:1) – increased with age, and 
that  this  change  cannot  be   ascribed   to  confounding  
 
 
Figure 3. Plasma ceramide and estradiol concentrations 
in men and women. (A) Plasma ceramide levels in, left, pre-
menopausal women (20-54 years, n = 44) and age-matched 
men (19-54 years, n = 48) and, right, post-menopausal women 
(47-78 years, n = 40) and age-matched men (55-80 years, n = 
32). (B) Plasma estradiol levels in, left, pre-menopausal 
women (20-54 years, n = 44) and age-matched men (19-54 
years, n = 48) and, right, post-menopausal women (47-78 
years, n = 40) and age-matched men (55-80 years, n = 32). *p < 
.05, **p < .01, ***p < .001; 2-way ANOVA followed by 
Bonferroni post-hoc test (women 20-54 years versus men 19-
54 years). # p < .05, ## p < .01, ### p < .001; 2-way ANOVA 
followed by Bonferroni post-hoc test (women 20-54 years 
versus women 47-78 years). 
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Figure 4. Pearson’s correlation analysis between estradiol and levels of various ceramide species in plasma from 84 
women aged 20 to 78 years. (A) Ceramide (d18:1/24:1); (B) Ceramide (d18:1/24:0); (C) Ceramide (d18:1/16:0); (D) Ceramide 
(d18:1/18:0). Correlation is considered statistically signiﬁcant at p < .05. 
 
 
 
 
Figure 5. Pearson’s correlation analysis between estradiol and levels of various ceramide species in plasma from 80 
men aged 19 to 80 years. (A) Ceramide (d18:1/24:1); (B) Ceramide (d18:1/24:0); (C) Ceramide (d18:1/16:0); (D) Ceramide 
(d18:1/18:0). Correlation is considered statistically signiﬁcant at p < .05. 
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factors such as obesity, diabetes, and other health 
conditions. In men, the analysis revealed an association 
between age and ceramide (d18:1/24:1). Further 
analyses identified a significant negative correlation 
between circulating levels of estradiol and ceramide 
(d18:1/24:1) in women of all ages, but not in men. 
Finally, in vitro experiments showed that estradiol 
lowers ceramide levels in human cells expressing 
estradiol receptors. The findings suggest that aging is 
accompanied, in men and women, by an increase in the 
plasma concentrations of two ceramide species, 
(d18:1/24:0) and (d18:1/24:1), which are also known to 
be elevated in age-dependent pathologies such as 
atherosclerosis and cardiovascular disease [23, 24]. The 
results also point to the intriguing possibility that 
estradiol might control circulating ceramide levels in a 
sexually dimorphic manner.  
 
Previous studies have reported sex-dependent 
differences in plasma ceramides, but with somewhat 
contrasting results, which might be due to disparities in 
sex, fasting, age and body mass index across the studies. 
In a small investigation of blood serum samples from 10 
Caucasian volunteers (5 males aged 27-33 years and 5 
females aged 26-33 years), ceramide (42:1) was found 
to be higher in women compared to men [16]. Another 
study, performed on a much larger cohort of young 
Mexican Americans (1,076 individuals, 39.1% males, 
median age 35.7 years) [17], uncovered an association 
between  plasma  ceramides  and  sex after adjusting for  
Table 1. Sociodemographic and clinical characteristics of men and women included in the study. 
 
 
Whole sample 
(n=164) 
Men 
(n=80) 
Women 
(n=84) 
p-value 
Characteristic     
Age  
(years) 
 49.3±16.6 (range 19-80)  49.6±16.8 (range 19-80)  49.0±16.6 (range 20-78) .46 
Education  
(years) 
 14.4±3.8 (range 5-25)  14.6±4.0 (range 5-25)  14.2±3.7 (range 5-24) .85 
MMSE   29.4±1.0 (range 26-30)   29.4±1.0 (range 26-30)   29.4±1.0 (range 26-30) .82 
Ethnicity  
(% white) 
100.00 100.00 100.00  
Obesity  
(%) 
    0.00     0.00     0.00  
Diabetes  
(%) 
    0.00     0.00     0.00  
Current smokers  
(%) 
  14.02    7.50   20.23 .02 
Former smokers  
(%) 
  17.07   21.25   13.10 .21 
Hypertension  
(%) 
  19.51   20.00   19.05 1.00 
AHT  
(%) 
    7.32   11.25     3.57 .07 
Contraceptives  
(%) 
    3.66    0.00     7.14  
MMSE: Mini Mental State Examination. AHT: Anti-hypercholesterol therapy. Data are expressed as mean ± standard 
deviation (SD) or as %. Differences between groups are considered statistically signiﬁcant at p < .05; unpaired Student’s 
t-test for continuous variables; Fisher’s exact test for categorical variables.  
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Table 2A. Multivariable linear regression analysis to assess the association between individual ceramide 
species and variables (age, smoke, hypertension, contraceptive use, anti-hypercholesterol therapy) among 
women. 
 Ceramide 
(d18:1/16:0) 
Ceramide 
(d18:1/18:0) 
Ceramide 
(d18:1/24:0) 
Ceramide 
(d18:1/24:1) 
 β-coefficient 
(SE) 
p-value β-coefficient 
(SE) 
p-value β-coefficient 
(SE) 
p-value β-coefficient 
(SE) 
 p-value 
Covariates         
Age -0.08 (0.04) .0285   0.01 (0.02) .7805     5.67 (2.38) .0198    2.88 (0.61) <.0001 
Smoke -0.22 (0.98) .8237   0.01 (0.67) .9846   94.84 (65.56) .152    8.91 (16.74) .5963 
Hypertension  4.78 (1.42) .0012   2.48 (0.97) .0126  -41.14 (94.85) .6657 -20.60 (24.22) .3978 
Contraceptives  0.26 (1.86) .8896 -0.22 (1.27) .8606 -200.79 (124.34) .1104 -36.64 (31.76) .2521 
AHT  5.14 (2.63) .0544   2.76 (1.80) .1298 -144.71 (76.10) .4137 -51.18 (44.98) .2586 
SE: standard error. AHT: Anti-hypercholesterol therapy. N = 84. Differences are considered statistically signiﬁcant at p < .05.  
 
 
 
Table 2B. Multivariable linear regression analysis to assess the association between individual ceramide 
species and variables (age, smoke, hypertension, contraceptive use, anti-hypercholesterol therapy) among 
men. 
 Ceramide 
(d18:1/16:0) 
Ceramide 
(d18:1/18:0) 
Ceramide 
(d18:1/24:0) 
Ceramide 
(d18:1/24:1) 
 β-coefficient 
(SE) 
p-value 
 
β-coefficient 
(SE) 
p -value β-coefficient 
(SE) 
p-value β-coefficient 
(SE) 
p-value 
Covariates         
Age -0.05 (0.03) .1797 -0.03 (0.03) .3624      2.37 (2.50) .3456    1.86 (0.77) .0179 
Smoke -0.74 (1.14) .5199  0.25 (0.99) .7989     -1.46 (82.89) .986  18.25 (25.46) .4758 
Hypertension  0.77 (1.35) .5685  2.13 (1.14) .0659  132.70 (97.13) .176  42.58 (29.80) .1573 
AHT -2.08 (1.75) .2388 -0.79 (1.52) .6064 -189.47 (128.14) .1435 -77.42 (39.38) .053 
SE: standard error. AHT: Anti-hypercholesterol therapy. N = 80. Differences are considered statistically signiﬁcant at p < .05.  
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age and body mass index: ceramide levels were lower in 
women than in men. These disparities were mostly 
driven by long-chain ceramide species, such as 
(d18:1/22:0), (d18:1/24:0) and (d18:1/24:1). Finally, in 
a multiethnic population sample of 366 women and 626 
men aged over 55 years, enrolled in the Baltimore 
Longitudinal Study of Aging, plasma ceramide 
concentrations were found to be higher in women 
compared to men [18].  
 
These studies did not focus on age as a variable. By 
contrast, in the present work we set out to address the 
impact of aging on ceramide levels and excluded 
subjects with disease conditions that had been 
previously shown to affect ceramides, such as diabetes 
[25], cancer [26], renal disease [27], cardiovascular 
disease [28] and obesity [29]. We did not exclude 
subjects with hypertension, however, because the 
association of this disease state with altered ceramides 
remains to be fully established [11, 18]. In our sample, 
we were able to confirm the presence of age- and sex-
dependent differences in the plasma concentrations of 
certain ceramide species, but not others. A multivariable 
analysis showed that, in women, aging is accompanied 
by increased levels of ceramide (d18:1/24:0) and 
(d18:1/24:1). In men, the analysis also unmasked a 
statistically detectable association between age and 
ceramide (d18:1/24:1). These age-dependent changes 
could not be ascribed to obesity, diabetes, tobacco 
cigarette smoking and use of anti-hypercholesterol or 
contraceptive agents. Interestingly, secondary data 
analyses found that ceramide levels were significantly 
lower in female than male subjects aged 20-54, a 
difference that disappeared after menopause. In their 
2015 study, Mielke and collaborators did not 
specifically include menopause as a variable, but 
suggested that menopause and estradiol may influence 
ceramide levels [18]. Two sets of results presented here 
support this prediction. First, we showed that, in women 
of all ages, plasma estradiol was negatively correlated 
with ceramide (d18:1/24:1) and displayed a trend 
toward correlation with ceramide (d18:1/24:0). No such 
relationship was detectable in men. Second, we found 
that incubation with exogenous estradiol (10 nM) 
lowered the intracellular levels of various ceramides, 
including ceramide (d18:1/24:0) and (d18:1/24:1), in 
human estrogen-sensitive MCF7 cells.  
 
The findings outlined above suggest that age-dependent 
changes in estradiol may affect ceramide metabolism 
and/or transport in microsomal triglyceride transporter 
protein [30] differentially in men and women. The 
correlation between estradiol and ceramide raises the 
possibility that changes in the availability of certain 
ceramide species [e.g. ceramide (d18:1/24:1)] might be 
implicated in the reported cardioprotective, 
antihypertensive and neuroprotective effects of estradiol 
[31-33]. In this context, it is important to point out that 
increased plasma ceramide levels have been 
consistently linked to heightened risk of myocardial 
infarction and stroke [34]. Moreover, recent evidence 
indicates that alterations of ceramide levels may mirror, 
indirectly, ongoing neurodegenerative processes and 
might be used as a biomarker for Alzheimer’s disease 
development and progression [35]. Interestingly, the 
close association between alterations in ceramide levels 
and the likelihood of developing cognitive impairment 
and Alzheimer-related pathology may be particularly 
Table 3. Effects of estradiol on ceramide levels in MCF7 human breast cancer cells. 
 Vehicle Estradiol p-value 
Ceramide (pmol/mg protein) (pmol/mg protein)  
(d18:1/16:0) 57.4 ± 6.2 41.8 ± 0.8 .02 
(d18:1/18:0) 16.9 ± 1.3 13.3 ± 1.6 .12 
(d18:1/24:0) 209.4 ± 14.1 134.6 ± 7.4 .0002 
(d18:1/24:1) 265.6 ± 13.4 184.6 ± 12.6 .0006 
Cells were treated for 24 h with vehicle (0.1% DMSO in phenol-free DMEM) or 17-β-estradiol (10 nM) and ceramide 
levels were measured by LC-MS/MS. 
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strong in women, thereby indicating that sex-related 
mechanisms might participate in shaping the Alzheimer 
phenotype. Of note, elderly women show changes in 
plasma ceramide levels at the onset of their memory 
impairment [15]. In the past few years, the neurobiology 
of memory disorders has received increasing attention 
[36]. Memory deficits are often reported by women in 
temporal proximity of menopause [37], and recent 
findings indicate distinct changes in memory processing 
that appear to be linked more to the post-menopausal 
status than to chronological aging: in peri-menopausal 
women, the onset and progression of cognitive decline 
are often associated with a menopause-related decrease 
in estradiol levels [38]. Thus, the interplay between 
estradiol and ceramides, described here, may potentially 
be of broad significance for a variety of age-dependent 
disorders, including cardiovascular disease and 
cognitive impairment or any intersection of the two 
conditions [39]. 
 
The present study has several limitations. First, even 
though we excluded persons affected by obesity and 
diabetes, we did not collect information on metabolic 
factors that could potentially impact ceramide 
mobilization – such as adiposity, physical activity and 
levels of cholesterol, triacylglycerol and glucose in 
blood [18, 40-42]. Second, our study was focused on a 
specific subset of ceramides that we had previously 
found to be altered in the hippocampus of aged male 
and female mice [19]. This group of ceramides has been 
proposed as potential biomarker for cardiovascular risk 
[43], but is still only a small fraction of the vast number 
of ceramides produced by the body. Third, we measured 
total circulating levels of ceramides and did not attempt 
to separate ceramide pools bound to specific plasma 
lipoproteins [44]. It is possible that aging might exert an 
effect similar to obesity and diabetes, which have been 
shown to change the distribution of ceramides among 
lipoproteins [41].  
 
Our findings also raise a number of relevant questions, 
which should be addressed in future work. First, even 
though the results suggest that estradiol modulates 
ceramide mobilization in women, the precise 
mechanism and functional significance of this effect 
remain to be determined. One possibility is that 
activation of estrogen receptors results in the down-
regulation of de novo ceramide biosynthesis, for 
example by suppressing the expression of key enzymes 
such as serine-palmitoyltransferase and ceramide 
synthase [45]. Other possibilities are that estradiol 
might stimulate the expression of ceramide-hydrolyzing 
enzymes such as acid or neutral ceramidase or of 
ceramide-transporting proteins [30]. Probing the link 
between estradiol and ceramides will require additional 
experimentation, which may include measuring 
circulating ceramide levels in women throughout the 
menstrual cycle or assessing the impact of endogenous 
and exogenous estradiol on sphingolipid metabolism in 
female animals. At the functional level, studies are 
needed to correlate ceramide and estrogen levels to a 
broad panel of biomarkers (e.g., lipoprotein profile, C-
reactive protein) and clinical outcome measures (e.g., 
future adverse cardiovascular events and cognitive 
impairment) [43]. Without such information, the clinical 
significance of our findings remains speculative. 
Second, the lack of correlation between estradiol and 
ceramide (d18:1/18:0) and lack of association with age 
implies that this ceramide species, though elevated after 
menopause, may be subjected to a different regulation 
than ceramide (d18:1/24:1), whose levels are correlated 
with estradiol and are statistically associated with age. 
Third, we observed a substantial age-dependent 
decrease in plasma dihydroceramide (d18:0/24:0) in 
men aged 54-80 years. The significance of this finding 
is presently unclear, but warrants further attention. 
Fourth, we unexpectedly uncovered an association 
between hypertension in post-menopausal women and 
elevated levels of ceramide (d18:1/16:0) and 
(d18:1/18:0). While this result is consistent with 
previous reports [11], caution is warranted until studies 
with a larger cohort of pre- and post-menopausal 
women are performed. Finally, as mentioned above, the 
relation between ceramide levels and premorbid 
changes in cardiovascular, metabolic or cognitive 
function was not investigated in our study and deserves 
further investigations. Despite these unanswered 
questions, our results reveal the existence of a link 
between age, estradiol and ceramides, which might 
contribute to age-dependent pathologies in post-
menopausal women. 
 
MATERIALS AND METHODS 
 
Ethics statement 
 
Investigation has been conducted in accordance with the 
ethical standards and according to the Declaration of 
Helsinki and according to national and international 
guidelines and has been approved by the authors' 
institutional review board.  
 
Study subjects 
 
We recruited 164 Italian subjects (84 women) from 19 
to 80 years of age (Table 1). A primary criterion for 
subject selection was the absence of major medical 
illnesses and, particularly, conditions that had been 
previously linked to ceramide alterations. A subdivision 
of the subjects by age and menopause status is reported 
in Table S1. There were no significant differences 
between male and female subjects with regard to age, 
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years of education, ethnic background, cognitive status, 
as assessed by the Mini-Mental State Examination 
(MMSE), obesity and diabetes, hypertension and use of 
anti-hypercholesterol drugs. By contrast, there was 
difference in smoking status (20.23% women versus 
7.5% men). Moreover, 6 of 44 pre-menopause women 
used contraceptives at time of enrollment. None of the 
post-menopause women was under hormone 
replacement therapy (HRT).  
 
Exclusion criteria were: (i) suspicion of cognitive 
impairment or dementia based on MMSE [46] (score ≤ 
26, consistent with normative data collected in the 
Italian population) and confirmed by a detailed 
neuropsychological evaluation using the mental 
deterioration battery [47] and clinical criteria for 
Alzheimer’s dementia [48] or mild cognitive 
impairment [49]; (ii) subjective complaints of memory 
difficulties or other cognitive deficits, regardless of 
whether or not these interfered with daily life, as 
assessed by clinical evaluation; (iii) vision and hearing 
loss that could potentially influence testing results, as 
assessed by clinical evaluation; (iv) major medical 
illnesses (i.e., unstable diabetes; obesity; obstructive 
pulmonary disease or asthma; hematological and 
oncological disorders, as assessed by clinical evaluation 
and pertinent clinical testing; pernicious anemia; 
significant gastrointestinal, renal, hepatic, endocrine, or 
cardiovascular system diseases, as assessed by clinical 
evaluation and pertinent clinical testing; recently treated 
hypothyroidism, as assessed by clinical evaluation; (v) 
current or reported psychiatric disease, as assessed by 
the Structured Clinical Interview for Diagnostic and 
Statistical Manual of Mental Disorders, 4th Edition, 
Text Revision (DSM-IV-TR SCID) [50] or neurological 
disease, as assessed by clinical evaluation; and (vi) 
known or suspected history of alcoholism or drug 
addiction. Finally, because ceramides have been 
previously involved in the pathogenesis of 
neurodegenerative disorders [15, 51, 52], we excluded 
subjects who showed brain abnormalities or vascular 
lesions as determined by using a recently published 
semi-automated method [53]. The menopausal status 
was prospectively assessed during clinical interviews. 
Women were defined as post-menopausal when 
showing 12 consecutive months of amenorrhea that was 
not due to other obvious pathological or physiological 
causes. 
 
Blood collection and analyses were approved by the 
Santa Lucia Foundation Ethics Committee. A written 
consent form was signed by all participants after they 
received a full explanation of the study procedures. 
Informed consent has been obtained.  
Variables examined in relation to ceramide levels 
 
All variables were assessed for each patient using the 
same methods. Demographic variables considered in 
linear regression analysis included age and sex. Medical 
history covariates included hypertension, use of anti-
hypercholesterol agents and use of contraceptives. 
Current and former smoking status was ascertained by 
an oral interview. 
 
Chemicals 
 
Solvents and chemicals were purchased from Sigma 
Aldrich (Milan, Italy). Ceramide standards were from 
Avanti Polar Lipids (Alabaster, AL, USA).  
 
Blood collection 
 
Blood was drawn by venipuncture in the morning after 
an overnight fast, and collected into 10-ml tubes 
containing spray-coated EDTA (EDTA Vacutainer, BD 
Biosciences, San Diego, CA, USA). Plasma was 
obtained by blood centrifugation at 400 × g at 4 °C for 
15 min. The plasma divided into aliquots was stored at 
−80 °C until analyses.  
 
Lipid extraction 
 
Lipids were extracted using a modified Bligh and Dyer 
method [54]. Briefly, plasma samples (50 µL) or cell 
pellets were transferred to glass vials and liquid-liquid 
extraction was carried out using 2 mL of a 
methanol/chloroform mixture (2:1 vol/vol) containing 
the odd-chain saturated ceramide (d18:1/17:0) as an 
internal standard. After mixing for 30 s, lipids were 
extracted with chloroform (0.5 mL), and extracts were 
washed with liquid chromatography-grade water (0.5 
mL), mixing after each addition. The samples were 
centrifuged for 15 min at 3500 x g at room temperature. 
After centrifugation, the organic phases were collected 
and transferred to a new set of glass vials. To increase 
overall recovery, the aqueous fractions were extracted 
again with chloroform (1 mL). The two organic phases 
were pooled, dried under a stream of N2 and residues 
were dissolved in methanol/chloroform (9:1 vol/vol, 
0.07 mL). After mixing (30 s) and centrifugation (10 
min, 5000 x g, room temperature) the samples were 
transferred to glass vials for analyses. 
 
Ceramide quantification 
 
Ceramides were analyzed by LC-MS/MS using an 
Acquity® ultra-performance liquid chromatography 
(UPLC) system coupled to a Xevo triple quadrupole 
mass spectrometer interfaced with electrospray 
ionization (Waters, Milford, MA, USA), as previously 
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described [54]. Lipids were separated on a Waters 
Acquity® BEH C18 column (2.1 × 50 mm, 1.7 μm 
particle size) at 60 °C and eluted at a flow rate of 0.4 
mL/min. The mobile phase consisted of 0.1% formic 
acid in acetonitrile/water (20:80 vol/vol) as solvent A 
and 0.1% formic acid in acetonitrile/isopropanol (20:80 
vol/vol) as solvent B. A gradient program was used: 
0.0–1.0 min 30% B, 1.0–2.5 min 30 to 70% B, 2.5–4.0 
min 70 to 80% B, 4.0–5.0 min 80% B, 5.0–6.5 min 80 
to 90% B, and 6.6–7.5 min 100% B. The column was 
reconditioned to 30% B for 1.4 min. The injection 
volume was 3 µL. Detection was done in the positive 
electrospray ionization mode. Capillary voltage was 3.5 
kV and cone voltage was 25 V. The source and 
desolvation temperatures were set at 120 °C and 600 °C 
respectively. Desolvation gas and cone gas (N2) flow 
were 800 L/h and 20 L/h, respectively. Plasma and cell-
derived ceramides were identified by comparison of 
their LC retention times and MS/MS fragmentation 
patterns with those of authentic standards (Avanti Polar 
Lipids). Extracted ion chromatograms were used to 
identify and quantify the following ceramides and 
dihydroceramides (d18:1/16:0) (m/z 520.3 > 264.3), 
(d18:1/18:0) (m/z = 548.3 > 264.3), (d18:1/24:0) (m/z = 
632.3 > 264.3), (d18:1/24:1) (m/z = 630.3 > 264.3), 
(d18:0/24:0) (m/z = 652.5 > 634.5) and (d18:0/24:1) 
(m/z = 650.5 > 632.5). Data were acquired by the 
MassLynx software and quantified using the 
TargetLynx software (Waters, Milford, MA, USA). 
 
Estradiol quantification 
 
Plasma 17-β-estradiol (E2) levels were quantified using 
a competitive binding immunoassay kit (Human E2 
ELISA kit, Invitrogen, Milan, Italy) following 
manufacturer’s instructions. Briefly, plasma samples, 
controls and standard curve samples (50 µL) were 
incubated with E2-horseradish peroxidase conjugate (50 
µL) and anti-estradiol antibody (50 µL) in a 96-well 
plate for 2 h, at room temperature, on a shaker set at 700 
± 100 rpm. Washing was carried out by completely 
aspirating the liquid, filling the wells with diluted wash 
buffer (0.4 mL) provided in the kit and then aspirating 
again. After repeating this procedure 4 times, 
chromogen solution (200 µL) was added to each well; 
reactions were run for 15 min and stopped adding 50 µL 
of the stop solution provided in the kit. Absorbance was 
measured at 450 nm and estradiol concentrations were 
calculated by interpolation from the reference curve.  
 
Cell cultures and treatment 
 
The MCF7 human breast cancer cell line [22, 55] was a 
kind gift of Dr. Gennaro Colella (Mario Negri Institute, 
Milan, Italy). Cells were cultured in phenol red-free 
Dulbecco’s Modified Eagle’s Medium (DMEM) (Gibco 
by Life Technologies, Carlsbad, CA, USA) 
supplemented with charcoal-stripped fetal bovine serum 
(10%) (Sigma Aldrich, Milan, Italy) to starve cells from 
steroid hormones (starvation medium), L-glutamine (2 
mM), and penicillin/streptomycin (100 µg/mL), in a 
humidified atmosphere (5% CO2, 37 °C). Cells were 
seeded in 6-well plates (3 x 105 cells/well) and cultured 
for 24 h. Estradiol (Sigma Aldrich, Milan, Italy) was 
dissolved in dimethyl sulfoxide (DMSO) and diluted in 
phenol red-free DMEM to a final concentration of 10 
nM (0.1% final DMSO concentration). After 24 h 
incubation, the media were removed, cells were washed 
with phosphate-buffered saline, scraped and centrifuged 
(800 x g, 4 °C, 10 min). Protein concentrations were 
measured using the bicinchoninic acid assay (Pierce, 
Rockford, IL, USA) and cell pellets were stored at -80 
°C until analyses. 
 
Statistical analyses 
 
Results are expressed as mean ± SEM (standard error of 
the mean). Sex differences in baseline demographic and 
health-related characteristics were examined using 
Fisher’s exact test for categorical variables and unpaired 
Student's t-test for continuous variables. Data were 
analyzed by unpaired Student's t-test or 2-way ANOVA 
followed by Bonferroni post-hoc test. Pearson’s 
correlation coefficient assessed the pairwise correlation 
between estradiol and ceramide levels. Significant 
outliers were excluded using the Grubbs’ test. 
Multivariable linear regression method was used to 
assess the association between ceramides and patients’ 
characteristics. Differences between groups were 
considered statistically signiﬁcant at values of p < .05. 
The GraphPad Prism software (GraphPad Software, 
Inc., La Jolla, CA, USA) and SAS 9.4 (SAS Institute, 
Cary, NC, USA) were used for statistical analyses.  
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SUPPLEMENTARY MATERIAL 
 
Table S1. Clinical characteristics of men and women included in the study divided by age or menopause 
status. 
 
 
Men 
19-54 years of age 
(n=48) 
Men 
55-80 years of age 
(n=32) 
Women 
pre-menopause 
(n=44) 
Women 
post-menopause 
(n=40) 
Characteristic     
Current 
smokers  
(%) 
10.4 
 
3.12 25 15 
Former 
smokers  
(%) 
6.25 46.8 6.8 20 
Hypertension  
(%) 
12.5 31.2 2.3 37.5 
AHT  
(%) 
2.08 25 0 7.5 
Contraceptives  
(%) 
0 0 13.6 0 
AHT: Anti-hypercholesterol therapy. Data are expressed as %.  
 
